Comparative Pharmacology
Head-to-head clinical analysis: DEXCHLORPHENIRAMINE MALEATE versus PROMETHAZINE PLAIN.
Head-to-head clinical analysis: DEXCHLORPHENIRAMINE MALEATE versus PROMETHAZINE PLAIN.
DEXCHLORPHENIRAMINE MALEATE vs PROMETHAZINE PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexchlorpheniramine maleate is a histamine H1 receptor antagonist that competitively blocks the effects of histamine at peripheral H1 receptors, reducing symptoms of allergic reactions such as vasodilation, increased vascular permeability, and smooth muscle contraction. It also has anticholinergic and sedative properties.
Promethazine is a phenothiazine derivative that acts primarily as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and local anesthetic properties. Its antiemetic effect is mediated through blockade of dopamine D2 receptors in the chemoreceptor trigger zone.
2 mg orally every 4-6 hours; maximum 12 mg/day
25-50 mg orally, intramuscularly, or rectally every 4-6 hours as needed; maximum 100 mg per dose
None Documented
None Documented
Clinical Note
moderateDexchlorpheniramine maleate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateTerminal elimination half-life is 20-24 hours in healthy adults, allowing once or twice daily dosing. Prolonged in hepatic impairment or elderly.
Terminal elimination half-life: 10-19 hours (average 12-15 hours). Clinical context: Requires repeated dosing for sustained effect; dosing interval typically every 6-12 hours.
Primarily renal (approximately 70-80% as unchanged drug and metabolites, mainly glucuronide conjugates); minor biliary/fecal elimination (20-30%).
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for approximately 25-30%.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic
Dexchlorpheniramine maleate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate."